

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61N 1/375, 1/372, 1/378		A2	(11) International Publication Number: WO 97/29802 (43) International Publication Date: 21 August 1997 (21.08.97)
(21) International Application Number: PCT/US97/02576 (22) International Filing Date: 19 February 1997 (19.02.97)		(81) Designated States: JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 60/011,870 20 February 1996 (20.02.96) US 60/012,019 20 February 1996 (20.02.96) US 60/011,868 20 February 1996 (20.02.96) US 60/011,869 20 February 1996 (20.02.96) US		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(71) Applicant (for all designated States except US): ADVANCED BIONICS CORPORATION [US/US]; 12740 San Fernando Road, Sylmar, CA 91342 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): RICHMOND, Frances, J., R. [CA/CA]; 90 Bagot Street, Kingston, Ontario K7L 3E5 (CA). LOEB, Gerald, E. [US/CA]; 90 Bagot Street, Kingston, Ontario K7L 3E5 (CA).			
(74) Agents: SAMPLES, Kenneth, H. et al.; Fitch, Even, Tabin & Flannery, Room 900, 135 S. LaSalle Street, Chicago, IL 60603 (US).			
(54) Title: IMPROVED IMPLANTABLE MICROSTIMULATOR AND SYSTEMS EMPLOYING THE SAME			
(57) Abstract			
<p>Improved implantable microstimulators covered with a biocompatible polymeric coating in order to provide increased strength to the capsule thereof and to capture fragments of the microstimulator should it become mechanically disrupted and to make the microstimulator safer and easier to handle are provided here. The coating may include one or more diffusible chemical agents that are released in a controlled manner into the surrounding tissue. The chemical agents, such as trophic factors, antibiotics, hormones, neurotransmitters and other pharmaceutical substances, are selected to produce desired physiological effects, to aid, support or to supplement the effects of the electrical stimulation. Further, provided herein are systems employing the improved microstimulators to prevent and/or treat various disorders associated with prolonged inactivity, confinement or immobilization of one or more muscles. Such disorders include pressure ulcers, venous emboli, autonomic dysreflexia, sensorimotor spasticity and muscle atrophy. These systems include external control means for controlling the operation of the microstimulators, said control means having memory means for programming preferred stimulation patterns for later activation by the patient or caregiver.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroun	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**IMPROVED IMPLANTABLE MICROSTIMULATOR
AND SYSTEMS EMPLOYING THE SAME**

Background of the Invention

5 Muscles serve a number of functions, most of which are dependent upon their regular contraction, which is in turn dependent upon their strength and health. For example, in addition to the well known functions of supporting the skeleton and permitting
10 movement, muscles serve to pad the force of bone protuberances against the skin, and they promote blood flow, particularly through deep blood vessels. In response to repeated contractions against a load, muscle fibers grow in cross-sectional area and develop
15 more force, and in response to repeated contraction over a long period of time, the oxidative capacity and blood supply of the fibers is enhanced.

 In normal individuals, muscles are activated to contract by electrical signals that are communicated
20 from the brain and spinal cord by way of muscle nerves. Many medical diseases, physical disabilities and cosmetic disfigurements arise from abnormal or absent electrical signals to the muscles. Such abnormal or absent electrical signals may be pathological or may
25 simply be due to prolonged immobility or confinement that restricts or prevents the voluntary movement of one or more muscles. Without normal, routine electrical stimulation, muscles atrophy, that is lose their normal size and strength. Also contributing to
30 muscle atrophy may be a wide range of other pathophysiological mechanisms, including absence of sustaining hormones and other endogenous trophic substances.

 Many situations exist in which voluntary
35 muscle contraction cannot be used effectively to operate, condition or strengthen muscles. The most extreme loss of voluntary muscle function occurs when the brain or spinal cord is injured by trauma, the growth of tumors or cerebrovascular accidents. In

- 2 -

patients suffering from these conditions, muscles become wholly or partially paralyzed because the electrical commands that are normally generated in the nervous system are no longer available to stimulate 5 muscle contractions. Less extreme degrees of muscle weakness and atrophy can come about when some of the nerve fibers supplying a muscle are damaged by disease or injury, or when the muscle is immobilized or voluntarily rested, for example by casting or bedrest, 10 in order to recover from an injury or surgical intervention involving a nearby body part, or other prolonged confinement or immobilization.

With respect to prolonged physical confinement or immobilization, the affect of muscle 15 non-use and atrophy frequently leads to two disorders that are particularly difficult to avoid and expensive to treat, pressure ulcers of the skin and subcutaneous tissues and retardation of the normal circulation of blood through deep vessels. Continual, unrelieved 20 pressure on localized regions of skin can result in the development of pressure ulcers of the skin and subcutaneous tissues, also known as bed sores or decubitus ulcers. Pressure ulcers are thought to occur when tissues underlying a site of pressure are deprived 25 of oxygen and nutrients because blood flow is impeded, and when the area is subjected to frictional and shearing forces associated with continuous rubbing and movement. Pressure ulcers vary in size and degree of damage from small regions of redness to deep craters of 30 tissue erosion passing through skin, connective tissues, muscle and even bone that can threaten the life of a patient by providing portals of entry for pathogenic organisms. They are often exacerbated in chronically paralyzed or bedridden patients because of 35 atrophy of the unused muscles that normally provide a degree of padding between the skin and underlying bony protuberances. The treatment of pressure ulcers often

requires prolonged, intensive medical care and occasionally extensive surgery, usually entailing further restrictions in the posture of the patient, which may further complicate medical and nursing care

5 and cause other complications.

As mentioned above, prolonged immobilization or physical confinement of a body part often also results in retardation of circulation of blood through deep vessels, particularly the veins in and around

10 muscles. For example, the failure to contract muscles in the limbs at regular intervals, as occurs normally when walking or standing, is known to cause stasis of blood in some veins. Venous stasis is a predisposing factor in the formation of clots in the veins. Such

15 deep venous thrombosis further compromises blood flow to the immobilized body part and can be the source of dangerous emboli to the heart and lungs. Thrombosed veins may also become chronically infected, posing a danger of septicemia. Examples of particular

20 populations of patients that are especially at risk for development of pressure ulcers and venous emboli include comatose and obtunded patients, patients who are confined by paralysis to bed or wheelchairs, bedridden patients who have medical or surgical

25 conditions that limit their activity, and elderly patients with limited mobility. To reduce complications in these patients, it is necessary to reestablish movement of the vulnerable body parts; however, these patients are either incapable of

30 voluntary movement or severely restricted in their ability to voluntarily move. Therefore, therapists often spend considerable time manipulating the passive limbs of these patients, but this is expensive and relatively ineffectual because it is the active

35 contraction of muscle that tends to pump blood through the veins and to maintain the bulk of the muscle.

- 4 -

It has long been known that muscle contractions can be elicited involuntarily by stimulating muscles and their associated motor nerves by means of electrical currents generated from 5 electronic devices called stimulators. This has given rise to various therapies that seek to prevent or reverse muscle atrophy and its associated disorders by the application of electrical stimulation to the muscles and their nerves via these stimulators. For 10 example, the field of research known as functional neuromuscular stimulation (FNS) or functional electrical stimulation (FES) has begun, which seeks to design and implement devices capable of applying electrical currents in order to restore functional 15 movement to paralyzed limbs. Similarly, therapies employing stimulators to regularly apply specific patterns of electrical stimulation to muscles in order to prevent or reverse atrophy are known.

Many of the earliest stimulators were bulky 20 and relied upon the delivery of large current pulses through electrodes affixed to the skin, a procedure that requires careful positioning and fixation of the electrodes to the skin and frequently produces disagreeable cutaneous sensations and irritation of the 25 skin. Additionally, such transcutaneous stimulation produces relatively poor control over specific muscles, particularly those that lie deep in the body. Thus, this procedure can be time-consuming, uncomfortable, and is generally useful only for muscles located 30 immediately beneath the skin.

It is also possible to stimulate muscles more directly by passing electrodes through the skin into the muscles or by surgically implanting self-contained stimulators and their associated leads and electrodes 35 in the body. These devices have many configurations, but most are large and have numerous leads that must be implanted and routed through the body to the desired

- 5 -

muscles using complex surgical methods. Further, they are expensive to produce and the invasive procedures required for their implantation are impractical for most patients because they increase rather than

- 5 decrease the required care and the danger of infection and other sources of morbidity in patients who are already seriously ill. Thus, such devices have been used primarily in patients with severe paralysis in order to demonstrate the feasibility of producing
- 10 purposeful movements such as those required for locomotion, hand-grasp or respiration.

More recently a new technology has been described whereby electrical signals can be generated within specific tissues by means of a miniature

- 15 implanted capsule, referred to as a "microstimulator", that receives power and control signals by inductive coupling of magnetic fields generated by an extracorporeal antenna rather than requiring any electrical leads. See, U.S. Patent Nos. 5,193,539; 5,193,540; 5,324,316; and 5,405,367, each of which is incorporated in its entirety by reference herein. These microstimulators are particularly advantageous because they can be manufactured inexpensively and can be implanted non-surgically by injection.
- 20 25 Additionally, each implanted microstimulator can be commanded, at will, to produce a well-localized electrical current pulse of a prescribed magnitude, duration and/or repetition rate sufficient to cause a smoothly graded contraction of the muscle in which the
- 30 35 microstimulator is implanted. Further, operation of more than one microstimulator can be coordinated to provide simultaneous or successive stimulation of large numbers of muscles, even over long periods of time.

While originally designed to reanimate

- 35 muscles so that they could carry out purposeful movements, such as locomotion, the low cost, simplicity, safety and ease of implantation of these

- 6 -

microstimulators suggests that they may additionally be used to conduct a broader range of therapies in which increased muscle strength, increased muscle fatigue resistance and/or increased muscle physical bulk are

5 desirable; such as therapies directed to those muscle disorders described above. For example, electrical stimulation of an immobilized muscle in a casted limb may be used to elicit isometric muscle contractions that would prevent the atrophy of the muscle for the

10 duration of the casting period and facilitate the subsequent rehabilitative process after the cast is removed. Similarly, repeated activation of microstimulators injected into the shoulder muscles of patients suffering from stroke would enable the paretic

15 muscles to retain or develop bulk and tone, thus helping to offset the tendency for such patients to develop subluxation at the shoulder joint. Use of microstimulators to condition perineal muscles as set forth in applicants' copending patent application,

20 Serial No. 08/007,521, filed 11/24/95, entitled "Method for Conditioning Pelvic Musculature Using an RF- Controlled Implanted Microstimulator", incorporated herein by reference, increases the bulk and strength of the musculature in order to maximize its ability to

25 prevent urinary or fecal incontinence.

In addition to the therapeutic use of microstimulators to promote contraction of specific, isolated muscles in order to prevent or remedy the disorders caused or contributed to by inactive muscles,

30 the administration of hormones, trophic factors and similar physiologically active compounds may also be useful. It is known that the extent to which a muscle will grow in response to any stimulation regime is affected by the hormonal and chemical environment

35 around the muscle. Muscle fibers have receptors for many physiologically active compounds that circulate normally in the blood stream or are released from nerve

- 7 -

endings. These trophic factors have significant effects on the nature, rate, and amount of growth and adaptation that can be expected of the muscle in response to stimulation, whether such is produced 5 voluntarily or by electrical stimulation. Perhaps the best-known of these hormones are the androgenic steroids often used by athletes to increase muscle bulk and strength; but other hormones such as estrogens and growth hormones are also known to affect muscle 10 properties. For example, the dramatic reductions in circulating estrogens and androgens that occur in women following menopause appear to account for decreases in the mass of muscles and bones, which can be slowed or even reversed by administering the deficient hormones 15 systemically.

Thus, the beneficial strengthening effects of electrical stimulation can be maximized by providing the affected muscles with a supportive hormonal environment for growth. These compounds can be 20 provided systemically by administering them orally or by injection. However, many such compounds are rapidly metabolized by the liver, so that high doses must be administered to achieve a desirable therapeutic effect. This can expose all tissues of the body, including the 25 liver, to high and perhaps poorly controlled levels of the compound, resulting in undesirable side-effects that may outweigh the desired actions of the agent. In one aspect, the present invention recognizes that this problem could be circumvented by using a more selective 30 method of drug delivery directed specifically to the electrically exercised muscles. Even if the introduced compound were ultimately to be cleared by absorption into the bloodstream, high concentrations would be produced only in the tissue around the target. A steep 35 dilutional gradient would ensure that other regions of the body were exposed to much lower levels of the administered compound. By providing a more conducive

chemical environment in the early stages of electrical therapy, it is expected that muscle atrophy could be reversed more rapidly and effectively. After muscle function has been reestablished, longer-term

5 performance of the muscle could be more easily maintained at the desired level by electrical stimulation alone or in combination with low-dose systemic replacement therapy.

The microstimulators described and claimed
10 herein are elongated devices with metallic electrodes at each end that deliver electrical current to the immediately surrounding biological tissues. The microelectronic circuitry and inductive coils that control the electrical current applied to the
15 electrodes are protected from the body fluids by a hermetically sealed capsule. This capsule is typically made of a rigid dielectric material, such as glass or ceramic, that transmits magnetic fields but is impermeable to water vapor.

20 Encapsulation in glass is an effective and inexpensive way to ensure a hermetic seal between the electronic components and the biological tissues. Methods for forming similar hermetic seals within the confined dimensions of the overall device are well-
25 known in the fabrication of industrial magnetic reed relays and diodes and have been described specifically for implantable microstimulators. See, e.g., U.S. Patent Nos. 4,991,582; 5,312,439; and 5,405,367, each of which is incorporated in its entirety by reference
30 herein. Such a hermetic barrier is important both to ensure good biocompatibility with the body and to protect the sensitive electronics from the body fluids that might destroy their function.

35 Unfortunately, however, glass and similarly brittle materials such as ceramic may crack or shatter as a result of externally applied forces or even residual stress in the crystalline structure of the

material itself. If such an event occurs within the body or during a surgical procedure, it is desirable to retain or capture the sharp fragments of the capsule and any internal components so that they do not

- 5 irritate or migrate into the surrounding tissues. In a testing or surgical environment in which devices are handled repeatedly, the hard, slippery surface of the glass capsule makes the device difficult to handle, and could increase the likelihood that the device will be
- 10 dropped or pinched with a force sufficient to break the glass. Therefore, in one aspect, the present invention provides a well-chosen biocompatible coating for the glass which would decrease the lubricity of the device and ensure that glass pieces resulting from device
- 15 fracture would be contained/captured in a protective sleeve.

The reaction of a living body to an intact foreign body such as an implanted microstimulator depends at least in part on the shape and texture of

- 20 the surface of the foreign body, as described, e.g., by Woodward and Salthouse (1986). The surfaces left by the manufacturing processes used for the implanted microstimulator are constrained by the nature of the materials and processes required to achieve the desired
- 25 electronic and mechanical characteristics of the device. Therefore, modification of the microstimulators' chemical nature and/or superficial physical contours to avoid, prevent and/or discourage an immunological response by the body, would be
- 30 advantageous. Additionally, in selecting an appropriate coating material the opportunity arises for the introduction of various chemical compounds, such as trophic factors and/or hormones, as discussed above, into or onto the coating. Such compounds could then
- 35 diffuse from the surface of the coating into the surrounding tissues for various therapeutic and diagnostic purposes, as previously mentioned.

Summary of the Invention

The present invention provides for the prevention and treatment of various disorders caused or exacerbated by abnormal or absent electrical signals to the muscles and apparatus useful therefore. In one aspect, the invention provides an improved microstimulator having a biocompatible polymeric coating on portions of its exterior, thereby reinforcing the mechanical strength of the microstimulator such that it may optionally be implanted deeply into the muscle, while also providing a means for capturing the fragments of the microstimulator should mechanical disruption occur. In preferred embodiments, the coatings provided herein are selected to improve the nature of the foreign body reaction to the implanted microstimulator by modifying its chemical surface, texture and/or shape.

The implantable microstimulators disclosed and claimed herein are preferably of a size and shape that allows them to be implanted by expulsion through a hypodermic needle or similar injectable cannula. The microstimulator includes a hermetically-sealed housing, at least two exposed electrodes, and electronic means within the housing for generating an electrical current and applying the electrical current to the exposed electrodes. The coating, as described in detail herein, is formed on at least a portion of the exterior of the microstimulator in contact with the hermetic seal.

In another aspect of the present invention, the improved microstimulator, in addition to providing electrical stimulation to the muscle within which it is implanted, is modified to provide a locally high level of one or more desired chemical agents or drugs. In a preferred embodiment, the polymeric coating covering a portion of the microstimulator's surface contains a chemical agent that is released gradually from said

coating. Thus, when the microstimulator is implanted within or adjacent to a muscle it produces an electrical current that activates the motor nerves and/or muscle fibers of the muscle while simultaneously

- 5 dispensing the chemical agent(s) in the vicinity of the active muscle fibers.

Further, in preferred embodiments, the improved microstimulator is designed to provide electrical stimulation over a period of many years and

- 10 to provide elution of the chemical agent(s) over a period of many days, weeks or longer without any percutaneous connections to the external world.

Release of the chemical agent from the coating of the microstimulator may be by diffusion or, alternatively,

- 15 may be at a predefined rate controlled by electrical signals produced by the implantable device.

In yet another aspect of the present invention, systems providing involuntary movement to muscles for the purpose of preventing, treating and/or

- 20 slowing the progress of various complications associated with muscle inactivity, especially inactivity due to prolonged physical confinement or immobilization, are provided. These systems employ one or more microstimulators non-surgically implanted in or
- 25 near one or more inactive muscles. Once implanted, the prescribing physician uses an external controller to command each of the implanted microstimulators to produce various output stimulation pulses in order to determine a pattern of stimulation that produces the

- 30 desired muscle contraction pattern. The external controller retains the programmed stimulation routine and, thereafter, administers the therapy on a regularly scheduled basis and/or whenever commanded to do so by the patient or any caregiver.

- 35 The systems provided herein are particularly useful for maintaining or improving the functional capacity of paralyzed, weak, immobilized or

underexercised muscle without requiring voluntary exercise and for preventing various complications of prolonged physical confinement, including but not limited to pressure ulcers, deep venous thrombosis, 5 autonomic dysreflexia and sensorimotor spasticity. For example, the implantable microstimulators are employed to stimulate specific muscles in order to reduce the incidence and accelerate the healing of pressure ulcers on the sacrum, heels and other bony 10 protuberances of bedridden or immobilized patients. Alternatively or additionally, the systems are employed to reduce the possibility of venous stasis and embolus formation by eliciting regular muscle contractions in the legs of the bedridden or otherwise immobilized 15 patient. Advantageously, these systems may be employed to produce the desired pattern of regular contractions in one or more muscles for periods of days or weeks without the need for ongoing, continuous patient or caregiver supervision.

20

BRIEF DESCRIPTION OF THE DRAWINGS

The above and other aspects, features and advantages of the present invention will be more apparent from the following more particular description 25 thereof, presented in conjunction with the following drawings wherein:

FIG. 1 diagrammatically illustrates one embodiment of a microstimulator coated with a polymeric coating in accordance with the present invention;

30 FIG. 2 shows another embodiment of a microstimulator coated with a polymeric coating wherein the coating extends over a portion of the electrodes;

FIG. 3 illustrates another embodiment of the implantable device of the present invention that 35 provides both electrical stimulation and release of a chemical agent;

- 13 -

FIG. 4 shows another embodiment of an implantable device in accordance with the present invention;

5 FIG. 5 diagrammatically illustrates an implanted microstimulator in muscle tissue and its control using an external controller;

10 FIG. 6 shows a variation of the invention wherein a battery is included within the implantable device to allow it to operate independently of the external controller;

FIG. 7 illustrates a preferred manner used to implant a microstimulator in accordance with the present invention;

15 FIG. 8 illustrates the general circumstances that give rise to pressure ulcers, and illustrates one preferred manner in which an implanted microstimulator, in accordance with the present invention, may be used to reduce pressure ulcer formation; and

20 FIG. 9 illustrates the general circumstances that give rise to venous stasis, and further shows a preferred manner in which an implanted microstimulator may be used and controlled, in accordance with the present invention, to prevent and treat such a condition.

25 Corresponding reference characters indicate corresponding components throughout the views of the drawings.

DETAILED DESCRIPTION OF THE INVENTION

30 The following description is of the best mode presently contemplated for carrying out the invention. This description is not to be taken in a limiting sense, but is made merely for the purpose of describing the general principles of the invention. The scope of 35 the invention should be determined with reference to the claims.

An implantable device 9 made in accordance with the present invention is illustrated in FIG. 1. The device 9 includes a narrow, elongated capsule 2 containing electronic circuitry 4 connected to 5 electrodes 6 and 8, which pass through the walls of the capsule at either end, together forming a microstimulator of the type disclosed and fully described in U.S. Patent Nos. 5,193,539; 5,193,540; 5,324,316 and 5,405,367, each of which is incorporated 10 herein, in its entirety, by reference. A coating 10 is applied over the longitudinal extent of the surface of the capsule 2. In the particular embodiment of FIG. 1, the ends of the coating 11 do not extend over the surface of electrodes 6, 8, so that the coating does 15 not change the overall profile of the microstimulator. The device 9 is shaped to permit its insertion through a tubular insertion cannula, such as a syringe, that can be passed transcutaneously into a target muscle with or without fluoroscopic guidance, as described 20 further below.

The capsule 2 may be made of glass or a similar dielectric material, such as ceramic, that can provide a hermetic barrier to the permeation of body fluids and water vapor into circuitry 4. The basic 25 design of the current-generating circuitry 4 is the same or similar to that described in the above-referenced patents, in which electrodes 6 and 8 may be continuously charged (through inductive coupling) by a programmable magnitude of direct current and may be 30 occasionally discharged so as to produce a large, brief stimulation pulse with a programmable magnitude and duration, which stimulation pulse is used for the activation of nearby motor nerve and/or muscle fibers.

The coating 10 of the improved 35 microstimulator is selected to both be biocompatible and to be elastic enough to provide some reinforcement to the capsule 2. Additionally, it is advantageous and

preferred that the material chosen to form the coating 10 serve to reduce the risk of injury from and to provide means for the capture of capsule fragments in the event the capsule is broken. Finally, it is

- 5 desirable that the coating 10 chosen reduces the lubricity of the device, as glass and ceramic materials, of which the capsule 2 is most often constructed, are slippery. It will be appreciated by those of skill in the art that several different
- 10 coatings are available having these characteristics. By way of example only and in no way to be limiting, the polymeric coating 10 may be formed of a silicone elastomer or a thermoplastic material, such as polyethylene, polyester, polyurethane or a fluorinated
- 15 carbon chain from the TEFILON family.

The preferred method of application of coating 10 or depends on its chemical composition and physical properties. For example, in one embodiment, the coating 10 is formed from a thin-walled extrusion 20 of silicone elastomer whose inside diameter is slightly smaller than the outside diameter of capsule 2. The extruded tubing is cut to the desired length and its diameter temporarily expanded by absorption of an appropriate solvent such as heptane, toluene or xylene.

- 25 The expanded silicone tubing is then slipped over the microstimulator, subsequently shrinking tightly onto the surface of the microstimulator as the solvent is evaporated from the silicone elastomer, thereby forming the desired coating 10.

- 30 In another embodiment, the coating 10 is made from a thermoplastic material such as a polyethylene, polyester, polyurethane or a fluorinated carbon chain from the Teflon family. A thin-walled extrusion of said thermoplastic material whose inside diameter is
- 35 smaller than the outside diameter of capsule 2 is mechanically expanded so as to temporarily increase its inside diameter. The expanded extrusion is then cut to

the desired length, slipped over the microstimulator, and caused to shrink onto the surface of the microstimulator by briefly heating it to the temperature at which it contracts toward its unexpanded 5 dimensions, thereby forming the desired coating 10.

In another embodiment, coating 10 is made from a liquid solution containing melted, dissolved or unpolymerized material which is applied to the surface of the microstimulator by dip-coating, injection 10 molding, or other suitable methods known to those of skill in the coating art. After covering the desired portions of the microstimulator, the coating 10 is allowed or caused to harden by appropriate means.

FIG. 2 shows an alternative embodiment of a 15 microstimulator 16 in accordance with the present invention. The microstimulator 16 of FIG. 2 is similar to the microstimulator 9 of FIG. 1 except that in FIG. 2 the ends 12 of coating 10 extend over electrodes 6, 8, thereby preventing concavities 14 from coming into 20 direct contact with tissues surrounding the implanted microstimulator. Advantageously, concavities 14 may be filled with a solid material, such as silicone or other material, to eliminate the presence of pockets of fluid that may act as a nidus of chronic infection.

FIG. 3 shows another embodiment of an 25 improved microstimulator 18 in accordance with the present invention. The microstimulator 18 of FIG. 3 is similar to the microstimulator 9 of FIG. 1 except that the coating 10 in FIG. 3 contains a chemical agent 20 30 which diffuses from the surface of the coating 10 into the surrounding tissues. The chemical agent 20 may be any of a large number of pharmacologic and diagnostic agents whose presence in the tissue surrounding the implantable microstimulator is desired as part of the 35 treatment received by the patient. Examples of suitable chemical agents 20 include anti-inflammatory or antibiotic compounds intended to reduce the foreign

body reaction, hormones, neuromodulators and neurotransmitters intended to potentiate the effects of the electrical currents, or dyes intended to mark the original location of the implanted microstimulator.

5 This list of agents provides only examples and is not intended to limit the scope of the invention set forth in the claims.

The method of introduction of the chemical agent 20 into or onto the coating 10 depends upon the 10 chemical nature of the agent and the selection of an appropriate coating material. In general, the types of agents and compatible coatings that may be used therewith are known to those of skill in the arts of chemical binding and diffusion and the design of 15 sustained release pharmaceuticals.

In a preferred embodiment, the chemical agent 20 comprises a long-acting suspension of testosterone, such as testosterone propionate, cypionate or enanthate. This agent 20 is mixed with or adsorbed 20 onto a silicone elastomer that is injection-molded or dip-coated and subsequently polymerized to provide a thin coating 10, which coating 10 is spread over a substantial portion of the surface area of the capsule 2. It should be appreciated that silicone is a highly 25 biocompatible compound that has been used previously to administer steroids to experimental animals without exposing the animals to the trauma of repeated injections. However, it should also be appreciated that coating 10 could be formed from a variety of other 30 materials, or by using a variety of other processes, as described above.

It is thus seen that in this preferred embodiment, agent 20 comprises a trophic compound used to enhance muscle development, specifically a 35 testosterone derivative. It should be appreciated that such compounds have been used for many years in humans to treat endocrine disorders or to retard the

development of estrogen-sensitive mammary tumors, and that a single intramuscular bolus of the compound will exert its actions for 2 to 4 weeks. The chemical agent 20 associated with the external coating 10 of the 5 present invention, however, could be selected from a variety of trophic chemicals with actions on muscle or connective tissues, and could be bound to the coating in any manner that advantageously affects its rate of release. The rate of release may be designed to be 10 anywhere from a few hours to a few days or weeks. Furthermore, agent 20 might actually consist of a multiplicity of active compounds, various of which affect or influence muscle fibers, nerve fibers, connective tissue, or inflammatory cells so as to 15 modify many aspects of the response of the tissues to the presence and activation of the device.

Certain composite materials, such as the drug-filled polymeric matrix that may be used for coating 10 the device, have the property that 20 electrical voltage influences a change in the rate at which the fillers diffuse from the matrix. Where it is desirable to use such compositions, the microstimulator illustrated in FIG. 2 is particularly useful, as the electrical output signals generated by circuit 4 are 25 applied, at least in part, to the coating 10 by its contact with the electrodes 6, 8 of the device. Such electrical output signals are systematically varied so as to produce the desired rate of elution of the chemical agent 20 into the tissues surrounding the 30 implanted device. Thus, it is seen that the electrical currents produced by electrodes 6 and 8 in the process of stimulating the muscle could also advantageously have the effect of increasing the elution rate of agent 20 simultaneously with the electrically-induced muscle 35 contraction.

As illustrated in FIG. 4, rate control of the elution of the chemical agent 20 from the coating 10

- 19 -

may alternatively be managed using additional electrodes 26 which are affixed to the capsule 2 and connected to the circuitry 4 of the device. Such additional electrodes provide for separate control of

5 the electrical currents and voltages applied to stimulate the muscle electrically and to control the rate of elution of chemical agent 20 from the polymeric coating 10. Advantageously, such multiple electrodes facilitate the use of electrophoretic current through

10 coating 10 to effect the release of agent 20, independent of the currents required to charge and discharge those electrodes associated with muscle or nerve stimulation. As illustrated in FIG. 4, electrode 26 is entirely covered by the polymeric coating 10,

15 whereas electrodes 6 and 8 are exposed to the body fluids. Electrical current applied between electrodes 26 and 8 would pass through coating 10 to effect electrophoretic release of chemical agent 20.

Electrical current applied between electrodes 6 and 8,

20 on the other hand, would pass unobstructed through the body fluids and tissues to effect electrical stimulation of nearby nerve or muscle fibers.

Referring now to FIG. 5, an improved microstimulator 28 is shown implanted into muscle 30.

25 In this embodiment, as well as in those of FIGS. 1-3, the improved microstimulator receives power from an external control device 40. The external control device 40 generates an alternating magnetic field, illustrated symbolically by the lines 36, through an

30 external coil 38, which coil may advantageously be located underneath the patient in a seat or mattress pad or in a garment or item of bedclothes. The magnetic field 36 is coupled with an implanted coil 33, which forms part of the microstimulator device 28, and

35 induces a voltage and current within the coil 33. The induced voltage/current in the coil 33 is used to power the electronic circuitry 4, and fluctuations (e.g.,

- 20 -

modulation) of the varying magnetic field 36 are used to control operation of the electronic circuitry 4. That is, the device 28 delivers current to its electrodes 6, 8 according to instructions encoded in 5 fluctuations of the magnetic field 36.

In this preferred embodiment, electrical current emitted from electrodes 6 and 8 stimulates motor nerve fibers 32. Muscle fibers themselves are relatively difficult to activate via such electrical 10 currents, but the motor nerve fibers are more readily stimulated, particularly if the microstimulator is located near them in the muscle. Each time a motor nerve fiber is excited, it conveys an electrical impulse through its highly branched structure to 15 synaptic endings on a large number of muscle fibers, which results in the activation of essentially all of those muscle fibers. Electronic circuit 4, then, controls the amplitude and duration of the electrical current pulse emitted by the microstimulator 28, 20 thereby determining the number of such motor nerve fibers that are excited by each pulse.

As an example of a preferred use of the improved microstimulator, the prescribing physician uses a programming station 44 to command external 25 controller 40 to produce various stimulation pulses, during the initial treatment session after implantation of the improved microstimulator 28. This is done in order to determine an exercise program that will provide the desired therapeutic muscle contraction 30 program for the individual patient. The exercise program is down-loaded into a memory element 42 of the external controller 40, where it can be reinitiated at will by, for example, manually activating control 46. This manual control may be performed, e.g., by the 35 patient or an attending caregiver. In the preferred embodiment, programming station 44 is a personal computer, external controller 40 contains a

microprocessor, and memory element 42 is a nonvolatile memory bank such as an electrically programmable read-only memory (EEPROM). However, it will be appreciated by those of skill in the art that many different 5 systems, architectures and components can achieve a similar function.

In accordance with a variation of the invention, shown in FIG. 6, a battery 46 is included within the implanted device (microstimulator), and is 10 employed as a continuous source of power for the electronic circuit 4. Such battery also provides storage and production means for a program of output currents and stimulation pulses that may then be produced autonomously by the implanted device without 15 requiring the continuous presence of extracorporeal electronic components, i.e., without the need for an external control device 40. In such instance, means would be provided for transmitting the desired program to each microstimulator and for commanding each 20 microstimulator to begin or to cease operating autonomously. Advantageously, such an embodiment as shown in FIG. 6 may provide for continuous biasing current or voltage applied to coating 10 (when at least one of the electrodes is positioned to contact the 25 coating 10, as shown in FIG. 2 above, or when a separate electrode is embedded in the coating 10 as illustrated in FIG. 4, above) so that the rate of elution of agent 20 would always be well-controlled.

In a preferred implantation method, the 30 microstimulator is injected into the muscle of interest through an insertion device whose preferred embodiment is shown in FIG. 7. The external cannula 110 of the insertion tool is comprised of a rigid, dielectric material with sufficient lubricity to permit the easy 35 passage of the microstimulator without scratching its external surface. The central trochar 120 of the insertion tool is an electrically conductive rod whose

sharpened point extends beyond the insertion cannula, where it can be used to deliver current pulses to the biological tissue near its point. The initial insertion of the tool is directed either by a knowledge 5 of musculoskeletal landmarks or radiographic imaging methods to approach the region of muscle 30 in which motor nerve fibers 32 enter. Optimally, the insertion device is advanced into the muscle in parallel with the long axis of muscle fiber fascicles. Electrical 10 stimuli may be delivered through the metallic trochar 120 by connecting a conventional electrical stimulator (not shown) to connector 122 on the trochar. By observing the contractions of the muscle 30, these test stimuli can be used to ensure that the tip of the 15 insertion device is situated sufficiently close to motor nerve fibers 32 to permit activation of a substantial portion of the muscle 30 without undesirable activation of other muscles or nerves. Failure to elicit the desired muscle contractions would 20 suggest a poor site of placement for the microstimulator and a need to reposition the insertion tool closer to the site of motor nerve entry.

When the desired position is reached, the trochar 120 is removed from cannula 110, taking care to 25 keep the cannula 110 in position within muscle 30, and a microstimulator is pushed through cannula 110 and into muscle 30 using a blunt-ended push-rod 130.

As stated above, the microstimulators provided herein are particularly useful in the 30 prevention and treatment of various disorders associated with prolonged immobilization or confinement; such as muscle atrophy, pressure ulcers and venous emboli. Referring to FIG. 8, there is illustrated, in diagrammatic form, the general 35 circumstances that give rise to pressure ulcers and a preferred embodiment whereby one or more microstimulators may be employed to reduce the

incidence of and/or contribute to the healing of such pressure ulcers. As depicted in FIG. 8, force 52 applied between bone 50 and firm support surface 56 is transmitted through intervening soft tissues of the

5 skin 34 and muscle 30, resulting in compression of skin region 54. Skin region 54 is thus in danger of developing a pressure ulcer. Active contraction of muscle 30 is induced by electrical stimulation applied by microstimulator 48 and its associated electrodes 6

10 and 8. Such active contraction makes muscle 30 stiffer, causing force 52 to be dissipated over a larger region of the skin 34. Further, active contraction of muscle 30 tends to shift the position of the body with respect to surface 56, causing force 52

15 to be directed to a fresh region of skin 34. Regular active contraction of muscle 30 induces various trophic mechanisms in the muscle that maintain or even enhance the bulk and tone of muscle 30 in its passive state, thereby reducing the concentration of force 52 on skin

20 region 54.

To further aid in the prevention and/or treatment of the pressure ulcer, the microstimulator as described above and illustrated in FIGS. 3-6 employing a coating 10 having a chemical agent 20 associated therewith, may be used. In this alternative, the chemical agent 20 may be a trophic factor employed to improve the bulk and tone of the muscle 30 or may be an antibiotic or similar therapeutic drug useful for preventing infection of the pressure ulcer, or the

25 chemical agent may be a combination of the two different agents. Increasing the bulk and tone of the muscle 30, can provide additional padding between the bone 50 and support surface 56, thereby lessening the force 52 against the skin region 54.

30 35 In the embodiment illustrated in FIG. 8, a microstimulator 48 has been injected into muscle 30 at (or very near) the skin region site 54 where a

potential pressure ulcer may develop. However, it may be satisfactory (or even preferred in some instances) to inject one or more microstimulators into adjacent muscles or near various nerves that control muscle 30 5 and/or other muscles that can affect the magnitude and direction of force 52 upon various regions of skin 34.

It should be appreciated that contraction of many different muscles and groups of muscles tends to lift the prominence of bone 50 so as to distribute the 10 load of the body more evenly across the skin 34, thereby reducing the amount of force 52 applied at a particular skin region 54. Optimally, a particular temporal pattern of stimulation applied by one or more microstimulators generates a sustained contraction of 15 the respective muscles that is maintained for several seconds to permit blood flow into vulnerable tissues. Such is accomplished by the extracorporeal components illustrated in FIG. 5 and described above. Thus, upon an external command or at predetermined intervals, 20 power and command signals sent from controller 40 cause the various microstimulators to emit a series of electrical current pulses (i.e., a pulse train) at the desired frequency and amplitude sufficient to cause the muscles to lift the body for the duration of the pulse 25 train.

Further movement of the body part typically occurs after cessation of such pulse-train stimulation because of various nervous reflexes or voluntary movements that are triggered by the concomitant 30 activation of various sensory nerve fibers resulting either from direct electrical stimulation of the sensory fibers or the mechanical consequences of the directly stimulated muscle activity. Such triggered movements are generally just as important, and may even 35 be more important, than the directly stimulated muscle activity caused by the microstimulator-generated pulse train for shifting body posture.

FIG. 9 illustrates the general circumstances that give rise to venous stasis and a particular embodiment for the use of microstimulators to reduce such stasis. Blood flow 64 in veins 66 running through 5 and between muscles 30, 62 depends in part on compressive forces 52 and general metabolic stimulation resulting from the occasional active contraction of muscles 30 and 64. In the absence of such contractions, flow is reduced, resulting in stasis and 10 an increased likelihood of the formation of clots or thrombi in the veins. One common site for this problem is in the calf muscles of the lower leg, which extend the ankle. In accordance with one aspect of the present invention, therefore, one or more 15 microstimulators are injected into the extensor muscles of the ankle, and one or more microstimulators are injected into the flexor muscles of the ankle. The programmed sequence of stimulation stored in memory bank 42 is used by controller 40 to create the 20 necessary transmission of power and command signals from coil 38 to cause the microstimulators injected into the ankle muscles to generate a prescribed stimulation sequence. Ideally, this prescribed sequence elicits muscle contractions sufficient to 25 shift the position of the foot alternately into extension and flexion for several seconds. The interval between the various muscle contractions and the strength and duration of the contraction in each muscle is set by an attending physician or 30 physiotherapist using a programming station 44 that downloads the desired program into memory bank 42. The rhythmic intermittent muscle contractions produced each time the program is activated causes compressive forces 52 to act on deep veins 66, augmenting venous flow 64 35 out of the muscle by a pumping action that reduces venous stasis.

It should also be noted that a particular pattern of stimulation applied through a particular microstimulator, or combination of microstimulators, may also be effective at reducing the incidence of both 5 pressure sores and venous stasis simultaneously, as well as generating other useful trophic effects on the muscles themselves, metabolic stimulation of the cardiorespiratory system, and improvements in the functioning of nervous pathways responsible for various 10 reflexive and autonomic functions commonly affected adversely by prolonged immobilization. Other specific dysfunctions that have been reported to be reduced by regular electrical stimulation of nerves and muscles include autonomic dysreflexia and sensorimotor 15 spasticity, particularly in patients suffering from spinal cord injury.

It should also be noted that the particular complications of pressure sores and venous stasis illustrated respectively in FIGS. 8 and 9 are intended 20 only to provide specific examples of the beneficial effects of regular, active muscle exercise that can be induced by microstimulators, and are not intended to limit the scope of the invention set forth in the claims regarding the utility of stimulation applied in 25 this manner. The present invention pertains generally to all beneficial effects that a caregiver might achieve by the appropriate implantation and programming of one or more microstimulators in any patient immobilized for a period of more than a few days.

30 While the invention herein disclosed has been described by means of specific embodiments and applications thereof, numerous modifications and variations could be made thereto by those skilled in the art without departing from the scope of the 35 invention as set forth in the claims.

CLAIMS

What is claimed is:

- 5 1. An implantable microstimulator comprising an hermetically-sealed housing; at least two exposed electrodes extending from said housing; electronic circuitry within said housing
10 coupled to said at least two exposed electrodes for generating electrical current and applying said electrical current to the two exposed electrodes; said microstimulator being of a size and shape capable of implantation by expulsion through a
15 cannula or hollow needle; and a polymeric coating that covers a substantial portion of the surface area of said hermetically-sealed housing.
- 20 2. The implantable microstimulator of Claim 1 wherein said coating does not contact said exposed electrodes.
- 25 3. The implantable microstimulator of Claim 1 wherein said coating contacts and covers a portion of the exposed electrodes.
- 30 4. The implantable microstimulator of Claims 1, 2 or 3 wherein said coating comprises a silicone elastomer.
- 35 5. The implantable microstimulator of Claims 1, 2 or 3 wherein said coating comprises a thin-walled extrusion of silicone elastomer forming a tube, said tube having an inside diameter that is slightly smaller than the outside diameter of the hermetically-sealed housing, which silicone tube is temporarily expanded by

absorption of an appropriate solvent so that it can be fitted over the hermetically-sealed housing.

6. The implantable microstimulator of Claims 1,
5 2 or 3 wherein said polymeric coating is made from a
thin-walled tubular extrusion of a thermoplastic
material having an inside diameter that is slightly
smaller than the outside diameter of the hermetically-
sealed housing, which silicone tubular extrusion is
10 temporarily expanded to slide over the hermetically-
sealed housing and then shrunk with heat to tightly fit
over the hermetically-sealed housing.

7. The implantable microstimulator of Claim 6
15 wherein said thermoplastic material is selected from
the group comprising polyethylene, polyester,
polyurethane and a fluorinated carbon chain from the
Teflon family.

20 8. The implantable microstimulator of Claims 1,
2 or 3 wherein said polymeric coating is made from a
liquid containing melted, dissolved or unpolymerized
material, which polymeric coating is applied to the
surface of the microstimulator in its liquid form and
25 then allowed to cure or harden to a solid form.

9. The implantable microstimulator of Claims 1,
2 or 3 wherein the nearby excitable tissue stimulated
by said microstimulator comprises motor nerve fibers or
30 muscle fibers.

10. The implantable microstimulator of Claims 1,
2 or 3 wherein said polymeric coating includes a
chemical agent therein that diffuses from the surface
35 of the coating into the surrounding tissue.

- 29 -

11. The implantable microstimulator of Claim 10 wherein said chemical agent is selected to improve the how the coated microstimulator is received within tissue after it is implanted.

5

12. The implantable microstimulator of Claim 10 wherein said pharmaceutical agent comprises a trophic substance that potentiates exercise effects of electrical stimulation.

10

13. The implantable microstimulator of Claim 12 wherein said trophic substance is selected from the group comprising androgenic steroids, testosterone, or long-acting compounds of testosterone.

15

14. The implantable microstimulator of Claim 10 wherein said coating is in contact with at least one electrode so that electrical currents or potentials applied to said at least one electrode are also applied 20 to said coating to modify the rate of release of the pharmaceutical agent from the coating.

15. The implantable microstimulator of Claims 1 or 10 wherein said electronic circuit means is powered 25 and controlled by external signals.

16. The implantable microstimulator of Claims 1 or 10 wherein said electronic circuit means includes a battery which allows operation of the electronic 30 circuit means in the absence of external signals.

17. The implantable microstimulator of Claim 10 comprising at least three electrodes, two of which are exposed, and a third of which is covered by said 35 coating.

- 30 -

18. A method of capturing fragments of a mechanically disrupted microstimulator comprising selecting a suitable material from which a biocompatible coating may be made, and covering 5 substantially all of the external surface of said microstimulator with said coating.

19. A system for the treatment of body tissue comprising:

10 (a) a microstimulator having a substantial portion of the surface thereof coated with a coating containing a pharmaceutical agent, said microstimulator including an hermetically-sealed housing, at least two exposed electrodes, and electronic circuit means for 15 generating electrical current/voltage that is applied to said electrodes;

(b) implantation means for implanting said coated microstimulator in body tissue to be treated; and

20 (c) control means for controlling said microstimulator to electrically excite a physiological response from the body tissue near the exposed electrodes simultaneously with elution of a locally high level of the pharmaceutical agent from the 25 coating.

20. The system of Claim 19 wherein the microstimulator coating is applied so that it contacts at least one of said exposed electrodes, whereby 30 electrical current/voltage applied to said exposed electrodes affects the rate at which the pharmaceutical agent is eluted from the coating.

21. A system for the prevention or reversal of 35 one or more disorders associated with prolonged inactivity, immobilization or confinement of one or more muscles, the system comprising:

(a) at least one implantable microstimulator, said microstimulator comprising a hermetically-sealed housing, at least two exposed electrodes for providing electrical current and 5 electronic means within said housing for generating electrical current applied to said exposed electrodes, and each microstimulator being of a size and shape capable of implantation by expulsion through a narrow cannula;

10 (b) implantation means useful for implanting said at least one implantable microstimulator into muscle tissue so as to be proximate a motor nerve fiber;

(c) external control means for commanding 15 the at least one implanted microstimulator to produce various stimulation pulses until a desired stimulation sequence and pattern are identified, said external control means having a memory element;

(d) storage means for storing the identified 20 stimulation sequence and pattern in the memory element of the external controller; and

(e) trigger means for triggering the stored 25 stimulation sequence and pattern from the external controller to provide regular electrically-induced contraction of the muscle each time such is desired.

22. The system of Claim 21, wherein said microstimulator is coated with a polymeric coating over a substantial portion of the surface area of the 30 hermetically-sealed housing.

23. The system of Claim 22, wherein the polymeric coating includes a chemical agent therein that diffuses from the surface of the coating into the surrounding 35 tissue.

- 32 -

24. The system of Claims 21, 22 or 23 wherein the disorder to be treated or prevented is muscle atrophy.

25. The system of Claims 21, 22 or 23 wherein the disorder to be treated or prevented is decreased muscle bulk, strength or fatigue resistance due to muscle inactivity.

26. The system of Claims 21, 22 or 23 wherein the disorder to be treated or prevented is one or more pressure ulcers.

27. The system of Claims 21, 22 or 23 wherein the disorder to be treated or prevented is one or more venous stasis conditions.

28. The system of Claims 21, 22 or 23 wherein the disorders to be treated or prevented are pressure ulcers and venous stasis conditions.

20

29. The system of Claims 21, 22 or 23 wherein the disorder to be treated or prevented is an autonomic dysreflexia condition.

25 30. The system of Claims 21, 22 or 23 wherein the disorder to be treated or prevented is a sensorimotor spasticity condition.

31. A system for the implantation of a microstimulator in muscle tissue so as to be near a motor nerve fiber comprising:

(a) a conductive trocar, injectable through a cannula into muscle tissue;

35 (b) electrical stimulus means for applying electrical stimulus to the conductive trocar to determine if it is satisfactorily situated sufficiently close to motor nerve fibers within the muscle tissue to

permit activation of a substantial portion of the muscle tissue; and

(c) a blunt-ended push-rod for pushing a microstimulator through the cannula, after careful 5 removal of said trocar from the cannula, wherein care is taken to keep the cannula in the satisfactory position within the muscle tissue.

32. A system for producing repeatable patterns of 10 electrical stimulation in order to contract one or more muscles, said system comprising:

at least one implantable microstimulator, said microstimulator comprising an hermetically-sealed housing, at least two exposed electrodes for providing 15 electrical current, and electronic means within said housing for generating electrical current, said microstimulator being of a size and shape capable of implantation by expulsion through a hypodermic needle; and

20 at least one control unit with memory means for retaining command information representative of at least one desired pattern of electrical stimulation, said control unit including means for coupling electrical signals to said microstimulator to provide 25 operating power and commands thereto for effectuating said desired pattern of electrical stimulation; and

actuator means within said control unit for sending the power and commands to the microstimulator which causes the microstimulator to provide the desired 30 pattern of electrical stimulation.

33. A method for reducing the incidence of medical complications resulting from prolonged physical inactivity, confinement or immobilization of the whole 35 body or parts thereof, comprising:

(a) implanting at least one microstimulator in muscle associated with an affected site, each

microstimulator comprising a hermetically-sealed housing, at least two exposed electrodes, and electronic means within said housing for generating an electrical current and applying said electrical current

5 to said exposed electrodes; and

(b) administering prescribed sequences of electrical stimulation through the electrodes of the implanted microstimulator to nerves or muscles in the vicinity of the implanted microstimulator.




FIG. 1




FIG. 2






FIG. 3

2/5



3/5




FIG. 5

4/5




FIG. 7




FIG. 8

SUBSTITUTE SHEET (RULE 26)




FIG. 9

This Page Blank (uspto)